News Room

Plexus Ventures Assists Fujifilm Kyowa Kirin Biologics in Partnering with Mylan of Humira® Biosimilar

April 24, 2018

Tokyo, Japan – Plexus Ventures is pleased to announce the successful conclusion of an out-licensing project of its client Fujifilm Kyowa Kirin Biologics Co., Ltd. Plexus Ventures provided professional services to Fujifilm Kyowa Kirin Biologics to partner the European rights for FKB327, a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics, with Mylan N.V.

“The opportunity to represent Fujifilm Kyowa Kirin Biologics in the partnering of their lead compound, whose Marketing Authorization Application is currently under review by the European Medicines Agency, is a great honor,” said Richard Brown, General Partner and Head, Tokyo Office of Plexus Ventures. “The high-quality development and manufacturing of FKB327 and the excellent reputation of Fujifilm Kyowa Kirin Biologics and its parent companies, FUJIFILM Corporation and Kyowa Hakko Kirin Co., Ltd., distinguishes FKB327 from other adalimumab biosimilars under development.”

President and CEO of Fujifilm Kyowa Kirin Biologics, Dr. Yoshifumi Torii, remarked, “We are very pleased with the strong and knowledgeable support of Plexus Ventures in all phases of the process leading to this important agreement with Mylan. Plexus Ventures’ broad industry network allowed us to select the optimal partner for commercializing FKB327 in Europe.”

Details regarding the transaction are provided in the press release of Fujifilm Kyowa Kirin Biologics: []

About Plexus Ventures

Now in its 28th year, Plexus Ventures provides strategic advice, business development and alliance management services to clients in the pharmaceutical, consumer healthcare and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Barcelona, Basel, Beijing, Indianapolis, London, Los Angeles, Milan, Oxford, Philadelphia, Sao Paulo and Tokyo, Plexus Ventures possesses the capabilities to effectively serve clients in North America, South America, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.